Dernières nouvelles pour Clarivate (NYSE:CLVT) Stock

Clarivate

Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas while Europe, Middle East, and Africa account for around a quarter.

Clarivate PLC

News

Management

Dana Appoints Current Director R. Bruce McDonald As Chairman And CEO

<p>Universal Health Realty Income Trust (NYSE:&nbsp;UHT) announced today that its Board of Trustees voted to increase the quarterly dividend by $.005 and pay a dividend of $.735 per share on December 31, 2024 to shareholders of record as of December 16, 2024.</p>


Dividends

Universal Health Realty Income Trust Announces Dividend Increase From $0.73 To $0.735 Per Share

<p><strong>Blue Bird</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBD#NASDAQ">BLBD</a>) reported its Q4 earnings results on Monday, November 25, 2024 at 04:00 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Blue Bird missed estimated earnings by -16.0%, reporting an EPS of $0.77 versus an estimate of $0.92.</p>
<p>Revenue was up $47.25 million from the same period last year.</p>
<h3>Analysis of Past Earnings</h3>
<p>In the previous quarter, the company beat on EPS by $0.4, resulting in a 0.0% increase change in the share price the following day.</p>
<p>Here's a look at Blue Bird's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.51</td>
<td>0.48</td>
<td>0.37</td>
<td>0.48</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.91</td>
<td>0.89</td>
<td>0.91</td>
<td>0.66</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>328.60M</td>
<td>298.41M</td>
<td>275.13M</td>
<td>290.11M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>333.37M</td>
<td>345.92M</td>
<td>317.66M</td>
<td>302.96M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Blue Bird <a href="https://www.benzinga.com/quote/BLBD/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings

BLBD

Blue Bird Earnings Review: Q4 Summary

<p><strong>Woodward</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) reported its Q4 earnings results on Monday, November 25, 2024 at 04:00 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Woodward beat estimated earnings by 13.0%, reporting an EPS of $1.41 versus an estimate of $1.25.</p>
<p>Revenue was up $77.42 million from the same period last year.</p>
<h3>Analysis of Past Earnings</h3>
<p>The company beat on EPS by $0.12 in the last quarter, resulting in a 17.0% drop share price change the following day.</p>
<p>Here's a look at Woodward's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.51</td>
<td>1.32</td>
<td>1.10</td>
<td>1.31</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.63</td>
<td>1.62</td>
<td>1.45</td>
<td>0.84</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>853.82M</td>
<td>807.00M</td>
<td>748.29M</td>
<td>765.35M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>847.69M</td>
<td>835.34M</td>
<td>786.73M</td>
<td>777.07M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Woodward management provided guidance for FY 2025, expecting earnings between $5.75 and $6.25 per share.</p>
<p>To track all earnings releases for Woodward <a href="https://www.benzinga.com/quote/WWD/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Woodward Earnings Report: Q4 Overview

<p><strong>Enanta Pharma</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) released its Q4 earnings on Monday, November 25, 2024 at 04:01 PM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>Enanta Pharma beat estimated earnings by 4.0%, reporting an EPS of $-1.36 versus an estimate of $-1.41.</p>
<p>Revenue was down $4.33 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>The company beat on EPS by $0.38 in the previous quarter, leading to a 1.0% increase share price change the next day.</p>
<p>Here's a look at Enanta Pharma's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-1.45</td>
<td>-1.33</td>
<td>-1.19</td>
<td>-2</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-1.07</td>
<td>-1.47</td>
<td>-1.58</td>
<td>-1.33</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>17.18M</td>
<td>16.52M</td>
<td>21.28M</td>
<td>17.50M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>17.97M</td>
<td>17.05M</td>
<td>18.00M</td>
<td>18.93M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Enanta Pharma <a href="https://www.benzinga.com/quote/ENTA/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ENTA

Enanta Pharma: Q4 Earnings Insights

<p><strong>Central Garden &amp; Pet</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENT#NASDAQ">CENT</a>) announced its Q4 earnings on Monday, November 25, 2024 at 04:02 PM.</p>
<p>Here's a breakdown of the earnings report.</p>
<h3>Earnings</h3>
<p>Central Garden &amp; Pet beat estimated earnings by 10.0%, reporting an EPS of $-0.18 versus an estimate of $-0.2.</p>
<p>Revenue was down $80.66 million from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>During the previous quarter, the company beat on EPS by $0.11, leading to a 6.0% increase share price change the next day.</p>
<p>Here's a look at Central Garden &amp; Pet's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.21</td>
<td>0.80</td>
<td>-0.14</td>
<td>0.06</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.32</td>
<td>0.99</td>
<td>0.01</td>
<td>0.08</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.00B</td>
<td>887.42M</td>
<td>619.95M</td>
<td>735.32M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>996.35M</td>
<td>900.09M</td>
<td>634.53M</td>
<td>750.15M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Central Garden &amp; Pet <a href="https://www.benzinga.com/quote/CENT/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CENT

Insights into Central Garden & Pet Q4 Earnings

<p><strong>Pennant Park Investment</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNNT#NYSE">PNNT</a>) reported its Q4 earnings results on Monday, November 25, 2024 at 04:05 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Pennant Park Investment missed estimated earnings by 0.0%, reporting an EPS of $0.22 versus an estimate of $0.22.</p>
<p>Revenue was up $2.46 million from the same period last year.</p>
<h3>Analysis of Past Earnings</h3>
<p>During the previous quarter, the company beat on EPS by $0.01, leading to a 1.0% increase share price change the next day.</p>
<p>Here's a look at Pennant Park Investment's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.23</td>
<td>0.24</td>
<td>0.23</td>
<td>0.22</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.24</td>
<td>0.22</td>
<td>0.24</td>
<td>0.24</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>36.66M</td>
<td>36.34M</td>
<td>32.74M</td>
<td>34.83M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>37.00M</td>
<td>35.98M</td>
<td>34.34M</td>
<td>34.04M</td>
</tr>
</tbody>
</table>
</p>
<p><strong> Listen to the earnings announcement yourself by <a href="">clicking here</a>. </strong></p>
<p>To track all earnings releases for Pennant Park Investment <a href="https://www.benzinga.com/quote/PNNT/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PNNT

Recap: Pennant Park Investment Q4 Earnings

<p>The earnings results for <strong>PennantPark Floating Rate</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFLT#NYSE">PFLT</a>) for Q4 were made public on Monday, November 25, 2024 at 04:05 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>PennantPark Floating Rate missed estimated earnings by 0.0%, reporting an EPS of $0.32 versus an estimate of $0.32.</p>
<p>Revenue was up $19.79 million from the same period last year.</p>
<h3>Historical Earnings Summary</h3>
<p>During the previous quarter, the company missed on EPS by $0.01, leading to a 0.0% increase share price change the next day.</p>
<p>Here's a look at PennantPark Floating Rate's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.32</td>
<td>0.32</td>
<td>0.31</td>
<td>0.31</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.31</td>
<td>0.31</td>
<td>0.33</td>
<td>0.32</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>45.52M</td>
<td>39.45M</td>
<td>35.01M</td>
<td>34.59M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>48.51M</td>
<td>44.35M</td>
<td>37.97M</td>
<td>35.73M</td>
</tr>
</tbody>
</table>
</p>
<p><strong> Listen to the earnings announcement yourself by <a href="">clicking here</a>. </strong></p>
<p>To track all earnings releases for PennantPark Floating Rate <a href="https://www.benzinga.com/quote/PFLT/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PFLT

PennantPark Floating Rate Earnings Review: Q4 Summary

<p>The earnings results for <strong>StealthGas</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GASS#NASDAQ">GASS</a>) for Q3 were made public on Monday, November 25, 2024 at 09:10 AM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>StealthGas beat estimated earnings by 15.0%, reporting an EPS of $0.38 versus an estimate of $0.33.</p>
<p>Revenue was up $5.79 million from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>The company beat on EPS by $0.22 in the last quarter, resulting in a 2.0% drop share price change the following day.</p>
<p>Here's a look at StealthGas's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.53</td>
<td>0.24</td>
<td>0.30</td>
<td>0.15</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.75</td>
<td>0.53</td>
<td>0.29</td>
<td>0.16</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>39.20M</td>
<td>34.30M</td>
<td>33.90M</td>
<td>27.50M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>41.79M</td>
<td>41.56M</td>
<td>34.14M</td>
<td>34.65M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for StealthGas <a href="https://www.benzinga.com/quote/GASS/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


GASS

StealthGas Q3 Earnings Assessment

<p><strong>Fluence Energy</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) reported its Q4 earnings results on Monday, November 25, 2024 at 04:26 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Fluence Energy beat estimated earnings by 13.0%, reporting an EPS of $0.34 versus an estimate of $0.3.</p>
<p>Revenue was up $555.02 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>The company beat on EPS by $0.11 in the last quarter, resulting in a 15.0% increase share price change the following day.</p>
<p>Here's a look at Fluence Energy's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.11</td>
<td>-0.07</td>
<td>-0.13</td>
<td>-0.06</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0</td>
<td>-0.07</td>
<td>-0.14</td>
<td>0.02</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>455.51M</td>
<td>578.76M</td>
<td>407.61M</td>
<td>515.67M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>328.09M</td>
<td>623.14M</td>
<td>363.96M</td>
<td>672.98M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Fluence Energy <a href="https://www.benzinga.com/quote/FLNC/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


FLNC

Fluence Energy Earnings Review: Q4 Summary

Asset Sales

Spruce Power Holding Corporation Class A Common Stock

SPRU

NJR Clean Energy Ventures Announces The Sale Of Its Residential Solar Portfolio To Spruce Power Holding For $132.5M

<p>Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) reported quarterly earnings of $0.34 per share which beat the analyst consensus estimate of $0.31 by 9.68 percent. This is a 1600 percent increase over earnings of $0.02 per share from the same period last year.  The company reported quarterly sales of $1.23 billion which missed the analyst consensus estimate of $1.30 billion by 5.61 percent.  This is a 82.47 percent increase over sales of $672.98 million the same period last year.</p>


Earnings Beats

Earnings Misses

Fluence Energy Q4 2024 GAAP EPS $0.34 Beats $0.31 Estimate, Sales $1.23B Miss $1.30B Estimate

WIIM

SANW

S&W Seed shares are trading higher after the company announced it has finalized the voluntary plan of administration  process for its subsidiary, S&W Seed Company Australia.

<p>BBB Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TBBB#NYSE">TBBB</a>) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $0.03 by 233.33 percent.  The company reported quarterly sales of $784.20 million which beat the analyst consensus estimate of $776.51 million by 0.99 percent.</p>


TBBB

BBB Foods Q3 EPS $0.10 Beats $0.03 Estimate, Sales $784.20M Beat $776.51M Estimate

<p>As previously reported, S&amp;W Australia adopted a voluntary administration process on July 24, 2024, and on October 11, 2024 creditors of S&amp;W Australia approved a proposed Deed of Company Arrangement pursuant to which, among other things, 100% of the shares in S&amp;W Australia would be transferred to Avior Asset Management No. 3 Pty Ltd. The effective date of the DOCA is November 22, 2024.&nbsp;</p>


S&W Seed Finalizes Voluntary Plan Of Administration Process For Subsidiary S&W Australia; On November 22, S&W Entered Settlement Agreement In Exchange For Release From Intercompany Obligations Owed To S&W Australia

SMTC

Semtech shares are trading higher after the company reported better-than-expected Q3 adjusted EPS and sales, and provided Q4 EPS and revenue guidance above analyst estimates.

Semtech shares are trading higher after the company reported better-than-expected Q3 financial results and issued Q4 guidance with its midpoint above estimates.

<p>Astronics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRO#NASDAQ">ATRO</a>) ("Astronics" or the "Company") today announced that it intends to offer, subject to market and other conditions, $150 million aggregate principal amount of convertible senior notes due 2030 (the "Notes") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Astronics also expects to grant to the initial purchasers of the Notes an option to purchase up to an additional $15 million aggregate principal amount of the Notes, for settlement within a 13-day period beginning on, and including, the first date on which the Notes are issued.</p>


Offerings

ATRO

Astronics Corporation Announces $150M Convertible Senior Notes Due 2030 Offering

LESL

Leslie's shares are trading lower after the company reported worse-than-expected Q4 adjusted EPS and sales.

<p>The Q4 earnings report for <strong>Leslies</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LESL#NASDAQ">LESL</a>) was released on Monday, November 25, 2024 at 04:05 PM.</p>
<p>Here's what investors need to know about the latest announcement.</p>
<h3>Earnings</h3>
<p>Leslies missed estimated earnings by -82.0%, reporting an EPS of $0.02 versus an estimate of $0.11.</p>
<p>Revenue was down $34.51 million from the same period last year.</p>
<h3>Performance in Previous Earnings</h3>
<p>In the previous quarter, the company missed on EPS by $0.08, resulting in a 14.000000000000002% increase change in the share price the following day.</p>
<p>Here's a look at Leslies's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.42</td>
<td>-0.18</td>
<td>-0.21</td>
<td>0.18</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.34</td>
<td>-0.17</td>
<td>-0.20</td>
<td>0.14</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>615.41M</td>
<td>200.92M</td>
<td>169.61M</td>
<td>419.39M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>569.64M</td>
<td>188.66M</td>
<td>173.96M</td>
<td>432.37M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Leslies <a href="https://www.benzinga.com/quote/LESL/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Leslies Earnings Report: Q4 Overview

09:54 EST Clarivate (CLVT) trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market-moving br...

Clarivate trading halted, volatility trading pause

Morgan Stanley analyst Toni Kaplan lowered the firm's price target on Clarivate (CLVT) to $5 from $8 and keeps an Equal Weight rating on the shares...

Clarivate price target lowered to $5 from $8 at Morgan Stanley

Clarivate Plc (CLVT) Q3 2024 Earnings Call Transcript

Analyst Toni Kaplan of Morgan Stanley maintained a Hold rating on Clarivate (CLVT – Research Report), reducing the price target to $5.00. Toni Kapl...

Clarivate's Struggles: Declining Growth, Leadership Changes, and Uncertain Outlook Lead to Hold Rating

In a report released today, Manav Patnaik from Barclays maintained a Sell rating on Clarivate (CLVT – Research Report), with a price target of $4.0...

Barclays Keeps Their Sell Rating on Clarivate (CLVT)

Barclays lowered the firm's price target on Clarivate (CLVT) to $4 from $5 and keeps an Underweight rating on the shares. The company reported "poo...

Clarivate price target lowered to $4 from $5 at Barclays

In a report released today, Shlomo Rosenbaum from Stifel Nicolaus maintained a Buy rating on Clarivate (CLVT – Research Report), with a price targe...

Stifel Nicolaus Remains a Buy on Clarivate (CLVT)

Clarivate: Downgrade To Hold As Growth May Take A Long Time To Recover

Tracking Seth Klarman's Baupost Group Holdings - Q3 2024 Update

Tracking Al Gore's Generation Investment Management Portfolio - Q3 2024 Update

AMAT

AMZN

CBRE

CLVT

CPRI

FTRE

GDHLF

GOOG

GOOGL

HSIC

HTHT

JAZZ

LBTYA

LBTYB

LBTYK

MELI

MSFT

NTNX

RELY

SCHW

SNRE

SOLV

SOPH

TBPH

TOST

TRMB

TSMWF

TWLO

TYGO

VEEV

VRSN

VSAT

WDAY

Press Releases

Clarivate Repeats Success in Nobel Prize Predictions with Eight New Winners Identified by Citation Laureates Program

Clarivate to Report Third Quarter 2024 Results on November 6, 2024

Thompson Street Portfolio Company Silverchair Announces Agreement to Acquire Scholarone

Clarivate Reports Third Quarter 2024 Results

Clarivate Launches New Sustainability Research Solution

Clarivate Publishes 2023 Sustainability Report

Clarivate Healthcare Business Insights Unveils 2023 Revenue Cycle Award Winners

New Report from Clarivate and Healthcare Executive Explores Mainland China's Biopharma Revolution and Increasing Global Influence

Clarivate Reveals Highly Cited Researchers 2024 List

BioWorld by Clarivate Highlights Gaps in Women's Health Research and Investment in New Special Series

Comments

Clarivate

Actualités

Dernières nouvelles pour Clarivate (NYSE:CLVT) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL